Skip to content
  • Home
  • About Us
    • Mission & Values
    • Leadership
  • Science
    • Technologies
    • Pipeline
    • Partnership
  • News
  • Home
  • About Us
    • Mission & Values
    • Leadership
  • Science
    • Technologies
    • Pipeline
    • Partnership
  • News
Contact Us
  • Home
  • About Us
    • Mission & Values
    • Leadership
  • Science
    • Technologies
    • Pipeline
    • Partnership
  • News
Contact Us

Publication Category: Posters

ECFS (EYIM) 2026 Optimization of blocker oligonucleotides as therapies to correct consequences of deep intronic mutations

C. Felgerolle, K. Delétang, I. Pranke, B. Simmoneau, L. Damy, F. Becq, B.Duriez, P. Fanen, I. Sermet, M. Taulan-Cadars – Phymedexp, Inserm U1046 / U1151, CNRS – University of Montpellier, Creteil -France

ECFS 2025 – CFTR stabilizers as therapeutic tools in cystic fibrosis

– M. Sinane, K. Deletang, C. Felgerolle, C. Teko-Agbo, P. Boisguerin, M. Taulan-Cadars – Phymedexp, Inserm U1046, University of Montpellier, France.

Get in touch

Partner with us to
redefine
cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Request Information
Investor Relations

Email

contact@aceso-therapeutics.com

Headquarters

Montpellier, France

Pioneering first-in-class dual-therapy approaches for Cystic Fibrosis patients underserved by today’s standard of care.

Company

  • Home
  • About Us
  • Science
  • News

Legal

  • Terms of use
  • Privacy
  • Terms
  • Cookies

Contact

  • contact@aceso-therapeutics.com
  • Montpellier, France

© 2026 ACESO Therapeutics. All rights reserved.

Designed for a future where every CF patient has a therapy.